Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (81-90 of 303) with videos related to

Pageof 31
Sort By:
Cancer Medicine|February 7, 2020
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidenceSeonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, et al.
Investigational New Drugs|May 25, 2019
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancerBo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, et al.
Cancer Chemotherapy and Pharmacology|July 23, 2017
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitorsHee Kyung Kim, Mi Hwa Heo, Han Sang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteriaHae Su Kim, Ji Yun Lee, Sung Hee Lim, et al.
Oncotarget|October 7, 2015
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancerSilvia Park, Emma Langley, Jong-Mu Sun, et al.
Scientific Reports|February 7, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancerJi Eun Shin, Hyun Ae Jung, Sehhoon Park, et al.
Journal of Thoracic Disease|January 10, 2017
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutationsYoon Ki Cha, Ho Yun Lee, Myung-Ju Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2014
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in KoreaJin Ho Baek, Jong-Mu Sun, Young Joo Min, et al.
Scientific Reports|August 23, 2019
Predictive and Prognostic Value of <sup>18</sup>F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung CancerSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Plos One|March 8, 2013
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospitalYoon-La Choi, Jong-Mu Sun, Juhee Cho, et al.
Pageof 31

Showing results (81-90 of 303) with videos related to

Sort By:
Pageof 31
Cancer Medicine|February 7, 2020
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidenceSeonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, et al.
Investigational New Drugs|May 25, 2019
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancerBo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, et al.
Cancer Chemotherapy and Pharmacology|July 23, 2017
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitorsHee Kyung Kim, Mi Hwa Heo, Han Sang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteriaHae Su Kim, Ji Yun Lee, Sung Hee Lim, et al.
Oncotarget|October 7, 2015
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancerSilvia Park, Emma Langley, Jong-Mu Sun, et al.
Scientific Reports|February 7, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancerJi Eun Shin, Hyun Ae Jung, Sehhoon Park, et al.
Journal of Thoracic Disease|January 10, 2017
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutationsYoon Ki Cha, Ho Yun Lee, Myung-Ju Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2014
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in KoreaJin Ho Baek, Jong-Mu Sun, Young Joo Min, et al.
Scientific Reports|August 23, 2019
Predictive and Prognostic Value of <sup>18</sup>F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung CancerSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Plos One|March 8, 2013
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospitalYoon-La Choi, Jong-Mu Sun, Juhee Cho, et al.
Pageof 31